Making a decision to wait for more evidence: When the National Institute for Health and Clinical Excellence recommends a technology only in the context of research

Journal of the Royal Society of Medicine

Volumn 100, Issue 10, 2007, Pages 453-460

  Chalkidou, Kalipso ^a   Hoy, Andrew ^a   Littlejohns, Peter ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; LAPAROSCOPIC SURGERY; MEDICAL ETHICS; MEDICAL RESEARCH; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; REVIEW; TECHNOLOGY; TRAUMATIC BRAIN INJURY; UNCERTAINTY;

EID: 35748979414     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.100.10.453     Document Type: Review

References (35)

1. Kumar A, Soares H, Wells R, et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomized controlled trials by the Children's Oncology Group. BMJ 2005;331:1295
2. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomized placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005;365:1957-9
3. Chalmers I. Minimizing harm and maximizing benefit during innovation in health care: controlled or uncontrolled experimentation? Birth 1986;13:155-64
4. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. Pediatrics 2006;117:1640-9
5. UK Collaborative ECMO Trial Group. UK collaborative randomized trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348:75-82
6. Pearson SD, Miller FG, Emanuel EJ. Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA 2006;296:988-91
7. Carino T, Sheingold S, Tunis S. Using clinical trials as a condition of coverage: lessons from the National Emphysema Treatment Trial. Clin Trials 2004;1:108-14. Discussion 115-21
8. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 2006;25:1218-30
9. Glasziou PP. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category. Med J Aust 1995;162:33-6
10. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. NEJM 2003;348:583-92
11. Department of Health. A First-Class Service: Quality in the New NHS. London: DoH, 1998
12. Department of Health. Faster Access to Modern Treatment: How NICE Appraisal Will Work. London: DoH, 1999
13. Department of Health. Selection Criteria for Referral of Topics to NICE. London: DoH, 2006
14. National Institute for Health and Clinical Excellence. Research and Development Strategy. London: NICE, 2004
15. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-47
16. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004
17. National Institute for Health and Clinical Excellence. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management. London: NICE, 2007
18. National Institute for Health and Clinical Excellence. Clinical Guidelines Development Methods. London: NICE, 2006
19. National Institute for Clinical Excellence. NICE Framework Document. London: NICE, 2004
20. World Health Organization. WHO Review of the NICE Technology Appraisal Programme. Geneva: WHO, 2003
21. National Institute for Health and Clinical Excellence. Laparoscopic Surgery for Colorectal Cancer (TA017). London: NICE, 2000
22. National Institute for Health and Clinical Excellence. Laparoscopic Surgery for Colorectal Cancer - Review (TA105). London: NICE, 2006
23. National Institute for Health and Clinical Excellence. Liquid-based Cytology for Cervical Screening - Review (TA069). London: NICE, 2003
24. National Institute for Health and Clinical Excellence. Four Commonly Used Methods to Increase Physical Activity: Brief Interventions in Primary Care, Exercise Referral Schemes, Pedometers and Community-based Exercise Programmes for Walking and Cycling (PHI002). London: NICE, 2006
25. Campbell WB, Barnes SJ, Kirby RA, Willett AL, Wortley A, Lyratzopoulos G. Association of study type, sample size and follow-up length with type of recommendation produced by the NICE Interventional Procedures Programme. Int J Technol Assess Healthcare 2007;23:101-7
26. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ 2004;328:475-6
27. Palmer S, Smith PC Incorporating option values into the economic evaluation of health care technologies. J Health Econ 2000;19:755-66
28. Raftery J. Review of NICE's recommendations, 1999-2005. BMJ 2006;332:1266-8
29. National Institute for Clinical Excellence. Multiple Sclerosis - Beta Interferon and Glatiramer Acetate (TA032). London: NICE, 2002
30. Cooksey Review. Best Institutional Arrangements for the New Single Fund for Health Research in the UK. London: HM Treasury, 2006. Available at http://www.hmtreasury.gov.uk/independent_reviews/cooksey_review/ cookseyreview_index. cfm
31. http://www.pharmatimes.com/WorldNews/Articles/10016-Cooksey-review.aspx? src-WN
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659-72
33. Smith I, Procter M, Gelber R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36
34. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet 2007;369:3-5
35. Citizens' Council. Only in Research Draft Report. London: NICE, 2007